The now chronic nature of HIV has been a major advancement in AIDS care, but as with any chronic condition brings with it the recognition of other sequelae, including the HIV-associated neurocognitive disorder (HAND). In addition, as a natural consequence of the chronicity of infection and reduced new infection, the face of HIV infection is changing to an older population;soon over half of infected individuals will be 50 years of age or greater. As detailed in our Research Plan, we will now take the lessons others and we have learned about HIV and the brain and apply it to the changing epidemic - the graying of HIV, the nature of the effects on the brain of the chronic infection, means to treat HIV in the brain, and potential interaction with conditions linked to aging and other neurodegenerative disorders. We will set about this through the Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center as described in this proposal. We will accomplish four Action Items novel Biomarkers, the Role of Macrophages CNS Penetrating Antiviral Therapeutics, and the Effects on Chronic CNS Infection on Neurons, and support our investigators'research efforts through our Cores (Administrative, Biophysical Assessment Cells/Tissues/Animals, Developmental, International, Phenomics, Systems Biology, and Therapeutics). Our goals driven by our framework: researching of the chronicity of HIV infection in the CNS with a systems biology approach.
While HIV infected individuals are living longer, damaging effects of HIV persists on the brain, and as infected individuals age, may interact with other neurodegenerative disorders. Here we will investigate this change in the epidemic, and research new ways to diagnose, predict, treat, and prevent brain damage induced by HIV.
Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26 |
Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443 |
Domingo-Almenara, Xavier; Montenegro-Burke, J Rafael; Benton, H Paul et al. (2018) Annotation: A Computational Solution for Streamlining Metabolomics Analysis. Anal Chem 90:480-489 |
Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154 |
Spooner, Rachel K; Wiesman, Alex I; Mills, Mackenzie S et al. (2018) Aberrant oscillatory dynamics during somatosensory processing in HIV-infected adults. Neuroimage Clin 20:85-91 |
Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137 |
Guijas, Carlos; Montenegro-Burke, J Rafael; Warth, Benedikt et al. (2018) Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 36:316-320 |
Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276 |
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40 |
Showing the most recent 10 out of 374 publications